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1. Past
Heparin was first described by Howell and McLean when they 
studied a thromboplastin, a procoagulant substance from the brain 
and later from liver ([1], review). Jay McLean was aware of several 
research results from Germany reporting peptones from organs acting 
as thromboplastin [2]. During 1915 and 1916, working in the laboratory 
of WH Howell, he purified an agent from heparphosphatide, which 
contaminated the cephalins obtained also from other brain and 
heart tissues, without telling Howell the results [3]. When Howell 
became aware of the data of his student he went on to analyse the 
contaminated cephalin himself and identified anticoagulants, naming 
them antithrombin and heparin [4]. Two batches of the purified 
compound were injected intravenously into dogs to demonstrate the 
anticoagulant heparin inhibition of blood coagulation [5].
Reports on the prevention of postoperative venous thrombo-
embolism date back to the end of the 1930s. Crafoord et al reported 
the first prophylactic uses of repeated intravenous injections of 
heparin in postoperative medicine and in perinatal gynaecology 
[6]. Bauer described the efficacy of heparin injection by reducing 
the incidence of mortality to 1–4% in 16,495 patients between 1939 
and 1945, compared to 18% without heparin observed between 1929 
and 1938, at the Mariestad hospital in Sweden. A reduction of fatal 
pulmonary embolism (PE) was found from 47 of about 25,000 cases 
to 3 of about 16,000 cases ([7], reviewed in [1]).
Lessons from history:
 Heparin is standard of care for treatment of acute PE and DVT
 Heparin is standard of care for postoperative prophylaxis of VTE
 Vitamin K antagonists are effective for prevention for recurrent VTE
2. Present
Today, UFH and LMWHs are known to effectively prevent 
thrombo embolism in many indications including extracorporeal 
circulation with UFH and haemodialysis with UFH and LMWHs. 
LMWHs are more effective for the prevention of recurrent events 
of venous thromboembolism (VTE) for several months in patients 
with malignant disease compared to vitamin K antagonist (VKA). 
Heparins are administered by intravenous or subcutaneous appli-
cations and UFH requires laboratory adjustment to maintain the 
activated partial thromboplastin time (aPTT) within a therapeutic 
range of 1.5- to 2.5-fold prolongation – subcutaneous administration 
may be provided at fixed doses for treatment of acute VTE. UFH 
and LMWHs require the repeated determination of platelet count 
due to the development of type I or type II heparin-induced 
thrombocytopenia (HIT) [8]. LMWHs improve anticoagulant therapy 
compared to UFH in many indications as a result of adjustment for 
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A B S T R A C T
Heparin, whose discovery goes back one hundred years, was first detected as a thromboplastin from 
liver tissue, and its anticoagulant action was only identified later. The procoagulant action of heparin, 
which was later characterized as an immunologic reaction by binding to platelet-factor IV, presenting as 
heparin-induced thrombocytopenia, remains as a side effect. For more than 60 years heparin has been the 
immediate anticoagulant of choice in many clinical indications. Further development of heparins resulted 
in the production of low-molecular weight heparins and Fondaparinux, which substituted heparin for many 
indications and has received many more new indications, including administration for non-anticoagulant 
purposes. This development is still ongoing and has resulted in more than 300 registered clinical trials at 
the end of 2015. All types of heparins are still investigated in patients with impairment of renal function 
to improve the safety of treatment. New therapeutic strategies for the prevention and treatment of 
thromboembolism, as well as of the non-anticoagulant actions of natural and modified types of heparins, 
are studied intensively. The clinical study designs include treatment with vitamin-K and non-vitamin K oral 
anticoagulants. Consequently, heparins, low-molecular weight heparins and Fondaparinux play an important 
role in the human health care system.
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body weight, or when using fixed dosing, and exhibit side effects 
less frequently. Other limitations for both groups of heparins are any 
kind of haemorrhage, cutaneous allergic reactions, heparin-induced 
skin necrosis, decreased antithrombin levels, heparin-resistance, 
hair loss, increases in liver enzyme levels, thrombotic occlusions in 
any organ as presentation of HIT type II, and other side effects all of 
them occuring less frequently with LMWHs compared to UFH [9,10].
Fondaparinux is a synthetic pentasaccharide with high affinity to 
antithrombin and an elimination half-life of about 17 hrs following 
subcutaneous administration. Its efficacy and safety are similar or 
better than for LMWHs in several indications. It does not bind to 
platelet factor 4 (PF4) as UFH and LMWHs, which form a complex 
between UFH, or LWMHs with a PF4 tetramer, generating heparin-
PF4 antibodies. Only a few cases of HIT have been reported during 
therapy with Fondaparinux. In fact, Fondaparinux is used for 
patients with HIT and cutaneous allergic reactions to heparins to 
allow anticoagulation to be continued. Owing to its low molecular 
weight, Fondaparinux is mainly excreted by glomerular filtration and 
the elimination half-life is prolonged by decreased renal function. 
Other side effects relate to bleeding complications, which occur less 
frequently compared to LMWHs [11]. Fondaparinux is administered 
at fixed doses or adjusted for body weight classes in VTE treatment 
without laboratory-guided dose adjustment according to anti-factor 
Xa levels. Requirement of specific laboratory methods and systemic 
administration remain as limitations for therapy [12].
Lessons from use of heparins
 Heparin has to be administered at a dose prolonging aPTT 1.5- to 2.5-fold
 LMWHs are almost as effective and safe as heparin
 Incidence of HIT less frequent with LMWH compared to UFH
 Body weight adjustment of LMWHs dosage are well established
 Fondaparinux is almost as effective and safe as LMWHs
 HIT does not occur with fondaparinux only
3. Relevance of impaired renal function
The relevance of intact renal function for heparins increased with 
the development of different LMWHs and Fondaparinux (reviewed 
in [13]). Early reports described the elimination of heparins by 
as much as 30% as inactive desulfated compound. Elimination of 
sulfated polysaccharides such as heparins occurs through kidneys, 
the elimination being higher with decreasing molecular weight and 
also for the pentasaccharide Fondaparinux. For two of the LMWHs, 
comparative studies supported this hypothesis. Tinzaparin, with a 
higher molecular weight was excreted almost independently of the 
degree of renal function, in contrast to Enoxaparin with a lower 
mean molecular weight, which is excreted as a function of renal 
function. It is also reported that lowering the degree of sulfation of 
a polysaccharide renders renal elimination less important [13]. As 
the absolute number of negative charges per oligosaccharide may 
be independent of the molecular weight, it remains open which of 
the two characteristics influence renal elimination. This is, however, 
not important for clinical administration, because for Enoxaparin a 
50% reduction of dose is required at a creatinine clearance (CrCl) 
of <30 ml/min and Fondaparinux is contraindicated at this stage of 
reduced renal function. Clearance of Enoxaparin has been described 
as a function of renal elimination and of lean body weight. This 
was supported by findings that higher anti-factor Xa activity was 
maintained longer if subjects had been dosed according to anti-
factor Xa levels compared to conventional fixed dosing [14].
In the RIETE Registry (Registro Informatizado de la Enfermedad 
TromboEmbólica) multivariate analysis indicated that patients 
were at increased risk for all-cause death (odds ratio, 1.8) and fatal 
pulmonary embolism (odds ratio, 2.3) when treated initially with 
UFH for acute VTE compared to LMWH [15]. A relation to renal 
function was not reported.
The main disadvantage for elimination of heparins by impairment 
of renal function is the accumulation of the anticoagulant with 
an increased risk of bleeding complications. A meta-analysis 
confirmed the increased risk of bleeding for patients with renal 
insufficiency receiving LMWHs [16]. Twelve studies including 
almost 5000 patients found major bleeding in 5% of patients with 
CrCl <30 ml/min, compared to 2.4% in patients with CrCl >30 ml/min 
(odds ratio = 2.2, p = 0.013). The rate of major bleeding decreased with 
Enoxaparin dose reduction, either empirically or based upon anti-Xa 
monitoring. There were insufficient data to determine bleeding rates 
with Tinzaparin and Dalteparin. In the ExTRACT-TIMI 25 trial, the 
Enoxaparin dose was reduced for age ≥75 years (0.75 mg/kg SC BID) 
and with CrCl <30 ml/min (1 mg/kg once daily). Patients with CrCl 
<30 ml/min still demonstrated a trend towards more major bleeding 
despite the reduced Enoxaparin dose. Several additional studies 
in patients with acute coronary syndrome added that, despite 
reducing the dose of Enoxaparin by 50% at an age >75 years and a 
CrCl of 15 to 30 ml/min, this did not reduce the incidence of major 
bleeding compared to conventional dosing. In contrast, lowering 
the dose to less than 0.5 IU/ml as peak levels increased the 30-day 
mortality. Controversially, elevated anti-Xa levels did not predict 
major bleeding. Not all LMWH products are the same in regards to 
reliance upon renal elimination. Available data are not sufficient to 
support these conclusions for Tinzaparin and Dalteparin. In contrast, 
UFH does not rely on renal elimination and remains an option for 
treatment in patients with CrCl <30 ml/min [12,17,18].
LMWHs have been shown to be effective for anticoagulation in 
chronic intermittent haemodialysis [13]. The advantages of LMWH 
over UFH are a lower incidence of bleeding risk, lower incidence of 
thrombocytopenia, and improvement of hypertriglyceridemia [19]. 
Patients on chronic intermittent haemodialysis often suffer from an 
increased bleeding risk. In these patients LMWH may be beneficial 
[20]. Dalteparin, Enoxaparin, Certoparin and Nadroparin [21] are 
approved for anticoagulation in haemodialysis. Dosing differs 
among the LMWHs as well as the anti-factor Xa levels to be obtained 
during or at the end of dialysis. In contrast to UFH, nadroparin 
required no laboratory monitoring of anticoagulant activity owing 
to the reliable anticoagulant response following its administration. 
Compared with UFH, Nadroparin was beneficial in terms of lipid and 
possibly bone parameters. Nadroparin administered by a bolus dose, 
followed by a continuous infusion was also shown to be effective 
and safe in patients undergoing continuous renal replacement 
therapy for acute renal failure [21]. In the IRIS trial (Innohep in 
Renal Insufficiency Study) no significant accumulation was detected 
with age, bodyweight or creatinine clearance comparing Tinzaparin 
versus UFH [22]. The mean anti-Xa activity did not differ significantly 
between the patients who experienced clinically relevant bleeding 
and those who did not. The high proportion of high molecular weight 
moieties in Tinzaparin may account for its reduced dependence on 
renal elimination [23].
The influence of impairment of renal function on UFH and LMWH 
(Nadroparin) levels in plasma and urine was investigated in a small 
study at our centre in patients on chronic haemodialysis. Following 
a bolus of 5,000 IU UFH, all samples were taken at the end of dialysis 
after 4 hrs. The anti-factor Xa (aXa) activity of UFH in plasma and 
urine was determined using Coamatic assay (Instrumentation 
Laboratories, Kirchheim, Germany). The results showed that the 
expected plasma anti-factor Xa levels and activity of heparin in 
urine was below the detection limit of the assay. Heparin plasma 
levels did not correlate with creatinine clearance (CrCl) (Table 1).
Patients with renal impairment, but not on haemodialysis or 
LMWH received 36 mg Nadroparin once daily subcutaneously in 
the morning. Blood and urine samples were taken after 4 hours. The 
anti-factor Xa activity in plasma was about 0.17 IU/ml as expected 
(Table 2). The amount of Nadroparin present in the urine was below 
the detection limit of the method. The plasma concentration did 
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not correlate with the creatinine clearance. The lack of correlation 
between plasma concentration and creatinine clearance is the 
main result from these observations. The results of the excretion 
of heparin and LMWH into urine are not robust and remain to be 
analysed further.
Lessons from impaired renal function
UFH is excreted by kidneys less than LMWHs
aPTT control of UFH improves safety in renal impairment
 (prolongation of aPTT 1.5- to 2.5-fold)
LMWH preparations differ in renal impairment
 See instructions for every LMWHs preparation,
 aXa determination improves dose adjustment (0.2 to 0.6 IU/ML)
Fondaparinux requires dose reduction in renal impairment (by about 50%)
4. Future
Future perspectives for clinical administration refer to the anti-
coagulant and non-anticoagulant effects of heparin, low-molecular 
weight heparin and modified LMWHs; the clinical indications 
becoming more and more specific [24]. Searching ClinTrialsGov with 
“low-molecular-weight heparin” at the end of the year 2015 revealed 
a total of 376 studies assigned with an NCT-number by which they 
can be found with any Internet search engine. Of these, about 10% 
are published, 5% have not yet commenced and about 15% use a new 
oral anticoagulant as comparator. Of the remaining studies, about 
30% are reported in Table 3. It is of note that about two thirds of trials 
are ongoing in specific indications for prophylaxis or treatment of 
venous or arterial thrombosis and one third in indications unrelated 
to the anticoagulant effects of heparins.
4.1. Anticoagulant effects of heparins and clinical study designs
The ongoing studies include all LMWH preparations, heparin and 
Fondaparinux. Placebo may also be included in a few of the studies. 
Interestingly, the study designs cover dose finding, comparison of 
two LMWHs and laboratory-guided dose adjustment (Table 3).
Prophylaxis of thromboembolism is investigated in several medical 
indications with acutely or critically ill patients. The anti thrombotic 
effects in superficial thrombophlebitis are investigated with several 
LMWHs. This indication covers the antithrombotic and anti-
inflammatory effects of the heparins based on the patho physiology 
of the disease, which cannot be differ entiated in the clinical endpoint 
from occurrence of a new VTE event. In chronic kidney disease LMWHs 
and Fondaparinux are evaluated in several clinical studies.
Interestingly, in cardiology many specific indications are investi-
gated with specific study designs. The use of heparin and LMWHs 
during termination and re-introduction of oral anticoagulation with 
a vitamin-K antagonist is investigated in several studies. Studies in 
acute coronary syndrome, in atrial fibrillation for stroke prevention 
and in retinal vein occlusion are ongoing.
Clinical study programs are being run concerning the indication 
of DVT and PE on dose regimens, duration of prevention of recurrent 
VTE events and the use of LMWH in specific angiological indications. 
It is noteworthy that LMWHs are used in many studies investigating 
the efficacy and safety of direct oral anticoagulants (DOAC) as 
comparator (Table 3).
4.2. Non-anticoagulant effects of heparins and study designs
The non-anticoagulant action of glycosaminoglycans plays a 
major role in their biological activity. A series of symposia at Villa 
Vigoni began in 1991 covering many of these topics [25]. The 
participants of the 21st symposium published several articles within 
the last year concerning the analysis [26], synthesis [27] and action 
[28] of glycosaminoglycans.
Non-anticoagulant effects of LMWHs have been investigated in 
patients suffering from various types of cancer (Table 3). Many of 
them include chemotherapy and the endpoint of most studies is 
death. Secondary endpoints include the occurrence of VTE, major 
bleeding, thrombocytopenia and others.
A non-anticoagulant LMWH preparations seem to play a role in 
many indications before, during and after pregnancy. The presence 
of antiphoshpholipid antibodies is one of the inclusion criteria in 
many studies. Recurrent abortion may or may not be related to 
these antibodies. Repeated implantation failures may be caused 
by changes in the glycosaminoglycan structure of the vascular 
endothelium [29]. Many study designs were developed to focus on 
the many topics in the medical area (Table 3).
The interaction of heparins with selectins and other endothelial 
bound mediators of inflammation are manifold [30]. Many clinical 
studies were initiated and reported at the Glycosaminoglycan 
Symposia. Some of them are reported in Table 3.
Future applications of UFH and LMWHs include:
 - Improve use in initial treatment of VTE
 - Improvement of anticoagulation in extracorporeal circulation
 - Indications for laboratory guided prophylaxis or treatment of VTE
 - Rare location of VTE
 - Bridging therapy with vitamin-K antagonists
 - Bridging treatment in special indications with patients on DOAC
 - Long-term administration in patients with cancer and VTE
 - Administration during pregnancy
 - Non-anticoagulant actions in many other indications (Table 3)
5. Summary
Heparin remains one of the oldest drugs extracted from 
biological sources and used for treatment of many diseases related 
to thromboembolism and to many non-anticoagulant indications. 
Despite the development of new anticoagulants, such as the new 
group of direct oral anticoagulants, unfractionated heparins and 
LMWHs have their specific clinical indications.
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Table 1
Heparin activity in haemodialysis patients in plasma and urine samples if 
available
 Heparin
  n mean SD r-value with CrCl
CrCl ml/min 37 12.43 5.06 –
Plasma
 aXa activity IU/ml 58 0.18 0.15 0.03556
Urine
 aXa activity IU/ml 29 0.01 0.01 not determined
Table 2
Heparin activity in patients with renal impairment and prophylaxis of VTE with 
LMWH from plasma and urine samples
 LMWH
  n mean SD r-value with CrCl
CrCl ml/min 40 37.77 18.58 –
Plasma
 aXa activity IU/ml 55 0.17 0.16 0.07935
Urine
 aXa activity IU/ml 54 0.01 0.01 not determined
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Table 3
Selected studies registered in https://ClinicalTrials.gov, as of Dec 30th 2015
Surgery, VTE 
prophylaxis
Open reduction and internal fixation of 
ankle fractures
Thrombelastography to guide VTE 
prophylaxis following trauma
Pre-vs postoperative start of VTE 
prophylaxis in THR
Obesity, aXa levels
Wound drainage following total joint 
arthroplasty
Laparoscopic surgery
NCT01029821
NCT01050153
NCT00726570
NCT01714297
NCT01970202
NCT00909064
NCT01589146
Medical patients Acutely ill NCT00311753
NCT00445328
Thrombosis Superficial thrombophlebitis
Use of LMWH for thrombosis in medicine
NCT01245998
NCT00362947
NCT00203970
Chronic kidney 
disease
Haemodialysis
Pharmacokinetics
Hemofiltration
Prevention of VTE
NCT00750451
NCT00756145
NCT00413088
NCT00286273
NCT00927602
Cardiology Heparin bridging (pacemaker implantation)
Stroke and heparin bridging
Heparin bridging in mechanical valve 
replacement
Retinal vein occlusion
Coronary artery bypass grafting
Non-STEMI
Blood clotting after atrial septal closure
Stroke prevention
NCT02094157
NCT00432796
NCT00298285
NCT00732927
NCT00420667
NCT00922766
NCT01086046
NCT02159287
VTE Long term LMWH
Thrombectomy device in iliofemoral 
thrombosis, LMWH
Weight fixed dose LMWH
Portal vein thrombosis
NCT00689520
NCT02596555
NCT02414802
NCT02486666
NCT01631877
Pregnancy Recurrent pregnancy loss
Repeated implantation failures
Antiphospholipid antibody
Recurrent abortion in APL-syndrome
Postpartum VTE prophylaxis
Recurrent implantation failure
Thrombophilia, VTE prophylaxis
NCT01828697
NCT01051778
NCT00400387
NCT01924104
NCT00564174
NCT01626911
NCT01274637
NCT01588171
NCT00750451
NCT02607319
NCT00967382
Cancer Lung
Kidney
Pancreas
Brain
Liver and chemoembolization
Multiple myeloma
High risk cancer
Chemotherapy through catheter
Pharmacokinetics
NCT00475098
NCT00771563
NCT01061411
NCT00966277
NCT00135876
NCT00827554
NCT01518465
NCT00876915
NCT00006083
NCT00716898
VTE and cancer Acute VTE
Duration of prophylaxis of recurrent VTE
NCT00564174
NCT00450645
NCT01164046
NCT01817257
NCT00203580
Haematology Sickle cell, pain crisis
Heparin induced thrombocytopenia
NCT01419977
NCT00629733
Anti-
inflammatory 
effect
Paediatric cataract surgery
Pneumonia and sepsis
Chronic foot ulcer in diabetic angiopathy
Active ulcerative colitis
NCT00986076
NCT01532544
NCT00399425
NCT00765063
NCT00033943
